Cder ind nda reviews guidance the common technical document and good review practice
1 / 15

CDER IND - PowerPoint PPT Presentation

  • Uploaded on

CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice. John K. Leighton, Ph.D., DABT CDER/FDA. Overview. Current IND/NDA review process FDA/ICH guidance Common Technical Document CDER Pharmacology Good Review Practice. Review Team. Project Managers

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'CDER IND' - celine

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Cder ind nda reviews guidance the common technical document and good review practice
CDER IND/NDA ReviewsGuidance, The Common Technical Document and Good Review Practice

John K. Leighton, Ph.D., DABT



  • Current IND/NDA review process

  • FDA/ICH guidance

  • Common Technical Document

  • CDER Pharmacology Good Review Practice

Review team
Review Team

Project Managers

Medical Officers





Nonclinical studies
Nonclinical Studies

  • Pharmacodynamics/Pharmacology

  • Pharmacokinetics

  • Safety pharmacology

  • Toxicology

  • Genetic toxicity

  • Reproductive toxicity

  • Carcinogenicity

Goals of nonclinical ind studies
Goals of Nonclinical IND Studies

  • Identify starting dose

  • Identify organ toxicities and reversibility

  • Guide dosing regimens and escalation schemes

Pharmacology studies
Pharmacology Studies

  • Pharmacological activity determined in nonclinical studies is generally of low relevance to safety (IND) and efficacy (NDA) decisions.

  • Summary report,without individual animal records or individual study results, usually suffices.

Toxicology study design
Toxicology Study Design

  • Pivotal for safety/start dose decision.

  • Toxicology studies should mimic the schedule, duration, formulation, and route as that proposed for the clinical trial.

  • Conform to standard toxicology protocols.

  • Conduct according to GLP.

Initial ind development
Initial IND Development

  • Integrated pharmacology/toxicology summary.

  • Full tabulation of each toxicology study to support safety of proposed trial.

  • Pharmacogenomic data:

    • Start dose selection?

    • Choice of relevant species?

    • Identify biomarkers?

Ind nda stage

  • Long-term toxicology studies

  • Genetic toxicology panel completed

  • Reproductive toxicology

  • Carcinogenicity studies (if necessary)

  • Pharmacogenomic data:

    • Decrease study length?

    • Improve assessment of organ toxicity?

    • Provide mechanistic explanation of toxicity?

      Not replace standard assessment

Guidance fda ich

  • Represent current thinking of the Agency.

  • Recommendations/not requirements.

  • FDA Guidance

    • Draft (for comment purposes only)

    • Final


Fda ich guidance topics

IND format

Start dose selection

Acute toxicity testing

Electronic NDA submission


Genetic toxicity

Reproductive toxicity

Photosafety testing



FDA/ICH Guidance Topics

The common technical document
The Common Technical Document

  • Guidance describing harmonized format for technical documentation for registration in all three regions.

    • Modules 2-5 common to all regions

    • Reduces time and resources used to compile registration documentation

  • Use with other ICH and Agency guidance.

  • Allows for regional specific summaries.

Good review practice
Good Review Practice

  • Guidance for Reviewers: Pharmacology/Toxicology Review Format

  • Internal review format for IND and NDA primary reviews

  • Purpose

    • standardization of reviews across divisions

    • ensure that important information is captured

    • allows for continued assessment of IND

  • Consistent with ICH CTD


Good review practice general toxicology study
Good Review PracticeGeneral Toxicology Study

Results: Mortality

Clinical Signs

Body Weights

Food Consumption




Clinical Chemistry


Organ Weights

Gross Pathology




  • Different submission format for pivotal safety data.

  • Good review practices for evaluation of data; provides consistency among review divisions and transparency. GRP will need to consider interdiscliplinary review of pharmacogenomic data.

  • Pharmacogenomics may play an important role in safety assessment in future INDs and NDAs.